Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

FDA Restricts Sarepta's Duchenne Gene Therapy Elevidys, Adds Boxed Warning

The U.S. Food and Drug Administration (FDA) has imposed significant restrictions on Sarepta Therapeutics' gene therapy Elevidys for Duchenne muscular dystrophy (DMD), following reports of patient deaths linked to liver toxicity. The regulatory action includes the addition of a boxed warning and narrowing of the patient population eligible for treatment.

NoahAI News11/18/2025

Artios Pharma Secures $115M Series D to Advance Oncology Pipeline

Artios Pharma, a biotechnology company focused on developing novel cancer treatments, has successfully raised $115 million in a Series D financing round. The funding will primarily support the advancement of the company's oncology pipeline, with a particular emphasis on its lead program, alnodesertib.

NoahAI News11/18/2025

Sensei Biotherapeutics Announces Significant Downsizing and R&D Termination

Sensei Biotherapeutics, a Boston-based biotech company, has revealed plans for a substantial workforce reduction and the cessation of all research and development activities. The announcement, made in the company's third-quarter earnings report, marks a significant shift in Sensei's operations and future prospects.

NoahAI News11/18/2025

Boston Scientific and Siemens Healthineers Partner on Advanced Cardiac Imaging Catheter

Boston Scientific and Siemens Healthineers have announced a strategic partnership to develop and commercialize a next-generation intracardiac echocardiography (ICE) catheter. This collaboration aims to enhance cardiac imaging capabilities for structural heart procedures, potentially driving growth in Boston Scientific's Watchman device business.

NoahAI News11/18/2025

Pharmaceutical Industry Faces Wave of Layoffs and Restructuring Amid Market Challenges

The pharmaceutical and biotechnology sectors are grappling with a surge of workforce reductions and strategic realignments as companies adapt to shifting market dynamics and financial pressures. Recent months have seen a spate of layoffs affecting thousands of employees across the industry, with both major players and smaller firms streamlining operations to cut costs and refocus their priorities.

NoahAI News11/18/2025

Cytokinetics Joins Bristol Myers in Funding AHA Heart Registry, Prepares for Market Clash

Cytokinetics, a rising player in the cardiovascular drug market, has announced its financial support for the American Heart Association's (AHA) initiative to standardize care for patients with hypertrophic cardiomyopathy (HCM). This move comes as the company prepares to potentially launch its new drug, aficamten, setting the stage for a competitive face-off with Bristol Myers Squibb's (BMS) Camzyos.

NoahAI News11/18/2025

XenoTherapeutics to Acquire Repare Therapeutics in $78.2 Million Deal

In a significant move within the pharmaceutical industry, precision oncology company Repare Therapeutics has agreed to be acquired by XenoTherapeutics, a nonprofit biotech organization focused on regenerative medicine. The deal, announced on November 14, 2025, values Repare at $1.82 per share, totaling approximately $78.2 million based on the company's outstanding shares as of September 30.

NoahAI News11/18/2025

Ascension Invests Over $530M in Tennessee Healthcare Expansion

Ascension St. Thomas, a prominent healthcare provider in Tennessee, has announced a significant investment of more than $537 million across multiple projects in the middle of the state. This substantial commitment aims to enhance healthcare accessibility, upgrade technology, and expand inpatient capacity in three key counties: Davidson, Rutherford, and Montgomery.

NoahAI News11/18/2025

Sandoz's Biosimilar Tyruko Launches in US, Challenging Biogen's Tysabri

Sandoz has officially launched Tyruko, the first biosimilar to Biogen's multiple sclerosis (MS) treatment Tysabri, in the United States. This milestone marks a significant shift in the MS treatment landscape, potentially offering a more cost-effective option for patients while putting pressure on Biogen's blockbuster medication.

NoahAI News11/18/2025

AI-Powered Health Tech Merger Aims to Transform Patient Care and Physician Decision-Making

SymphonyAI Group has announced the merger of two of its healthcare technology companies, RhythmX AI and Get Well, to form GW RhythmX. This strategic move aims to create a comprehensive AI-driven platform for precision care and patient engagement, serving 150 health systems across the United States.

NoahAI News11/18/2025

Bayer Strengthens Ties with China, Opens Beijing Innovation Center

Bayer has unveiled its latest initiative to bolster its presence in the Chinese pharmaceutical market with the opening of the Bayer E-Town Open Innovation Center in Beijing. This move signifies a strategic push to tap into China's growing influence in global pharmaceutical research and development.

NoahAI News11/18/2025

Jazz's HER2 Drug Ziihera Shows Promise in Phase 3 Gastric Cancer Trial

Jazz Pharmaceuticals has announced positive results from its phase 3 HERIZON-GEA-01 trial, evaluating the efficacy of its HER2-targeted bispecific antibody, Ziihera (zanidatamab), in patients with HER2-positive gastroesophageal adenocarcinoma (GEA). The study, which compared Ziihera-based regimens to the current standard of care, has yielded results that Jazz describes as "practice changing."

NoahAI News11/18/2025

«1...34 35 36...67 »